The demand for new biotherapeutics continues to grow, and there’s an increasing need for Contract Development and Manufacturing Organizations (CDMOs) to provide smaller biopharmaceutical companies with a simple solution to bring their concepts into reality.
—
Tanvex BioPharma USA, Inc. has addressed this demand with the launch of Tanvex CDMO, a full-service CDMO that provides pre-clinical-to-commercial services and specializes in microbial- and mammalian-derived biologics and biosimilars.
Tanvex CDMO stands as a beacon of progress, consistently pushing the boundaries of what's possible in biomanufacturing. At the heart of this biotechnological journey are groundbreaking technologies, revolutionary processes, and cutting-edge methodologies that place Tanvex CDMO at the forefront of the industry.
Revolutionizing Biomanufacturing Technologies
Now as a CDMO, Tanvex BioPharma USA’s commitment to innovation is evident in its approach to bioprocessing technologies.
Tanvex serves startups to mid-size companies that lack their own resources to move from the idea phase to achieving approved drug status for their healthcare product. The company might have only launched recently, but it already has the capacity, expertise, and infrastructure to deliver a full suite of services to its clients.
The core services offered by Tanvex CDMO include:
- Cell line development (microbial and mammalian)
- Pre-formulation and drug product formulation development
- Mammalian cell culture process development and optimization
- Purification process development
- Product and process characterization
- Analytical and potency assay development
- GMP services (microbial- and mammalian-derived therapeutics)
- Lot release testing
- Regulatory support
- Quality control
The company harnesses the power of state-of-the-art equipment and advanced automation to streamline biomanufacturing processes. From cell line development to the final product, Tanvex CDMO leverages automation to increase efficiency, reduce production times, and ensure product consistency.
Next-Generation Analytical Tools
Founded in 2011, Tanvex BioPharma’s goal was, and is, to improve the accessibility of biologics to patients.
The company is now a biologics outsourcing solution that provides a range of biologic manufacturing and contract developing services, using the 100,000-square-foot facilities at its headquarters in the Sorrento Valley of San Diego, California to serve a greater audience in the industry.
Tanvex CDMO recognizes the pivotal role that analytical technologies play in ensuring the quality and consistency of biologics. The company integrates advanced analytical techniques like chromatography, establishment and validation of assay cell banks, and other sophisticated methods to optimize its processes and ensure quality control.
This attention to detail not only meets regulatory requirements but also ensures the production of high-quality biologics with unparalleled precision.
Investment in Talent and Research
A key driver of Tanvex CDMO's innovation journey is its investment in talent and research. The company attracts top-tier professionals in the biotechnology and manufacturing fields, fostering a culture of innovation and collaboration.
The company is committed to ongoing research, ensuring that its teams are informed of the latest scientific developments and positioning itself to implement cutting-edge technologies as they emerge.
Tanvex CDMO has undoubtedly taken a leading role in shaping the future of biomanufacturing. As the company continues to push the boundaries of innovation, it secures its position at the forefront of the industry and plays an important part in contributing to the evolution of biotechnology as a whole.
Contact Info:
Name: Tanvex BioPharma
Email: Send Email
Organization: Tanvex BioPharma
Website: https://tanvexcdmo.com/
Social Media:
LinkedIn: https://www.linkedin.com/company/tanvex-cdmo/about/
Release ID: 89122787
Should you come across any errors, concerns, or inconsistencies within this press release's content, we urge you to reach out without delay by contacting error@releasecontact.com. Our committed team will promptly address your feedback within 8 hours and take appropriate measures to resolve any identified issues or guide you through the removal process. Providing accurate and dependable information remains our utmost priority.
ncG1vNJzZmilkae4psDSZ5muq5mjsrS%2FyKeqopyVp3uku8xopZ6vo2TAtbvCpKpoqKWotaq6xmaZqK2ema6ztcSsZK2ZnquyuXnCnaSoZaNiwbOtyKWZpZmqnruoecinpaiukam2sLqMoqVmmpmkuqK61J%2BYnKylp7avs4xqZ2xrYWaAcoWQ